Abstract
Objective To characterize the SARS-CoV-2 testing cascade and associated barriers in three US states.
Methods We recruited participants from Florida, Illinois, and Maryland (∼1000/state) for an online survey September 16 – October 15, 2020. The survey covered demographics, COVID-19 symptoms, and experiences around SARS-CoV-2 PCR testing in the prior 2 weeks. Logistic regression was used to analyze associations with outcomes of interest.
Results Overall, 316 (10%) of 3,058 respondents wanted/needed a test in the two weeks prior to the survey. Of these, 166 (53%) were able to get tested and 156 (94%) received results; 53% waited ≥ 8 days to get results from when they wanted/needed a test. There were no significant differences by state. Among those wanting/needing a test, getting tested was significantly less common among men (aOR: 0.46) and those reporting black race (aOR: 0.53) and more common in those reporting recent travel (aOR: 3.35).
Conclusions There is an urgent need for a national communication strategy on who should get tested and where one can get tested. Additionally, measures need to be taken to improve access and reduce turn-around-time.
Competing Interest Statement
SHM reports personal fees from Gilead Sciences, outside the submitted work. SSS reports grants/products from Gilead Sciences and grants/products from Abbott Diagnostics, outside the submitted work.
Funding Statement
This work was supported by the Johns Hopkins COVID-19 Research Response Program. AW is funded by a Career Award at the Scientific Interface by the Burroughs Wellcome Fund and by the National Library of Medicine of the National Institutes of Health (DP2LM013102). SSS is funded by the National Institute on Drug Abuse (DP2DA040244).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health (IRB00012413) and all participants consented to participate.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from the corresponding author upon reasonable request.
